Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma

Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwandt, Anita, Wood, Laura S, Rini, Brian, Dreicer, Robert
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886329/
https://www.ncbi.nlm.nih.gov/pubmed/20616894
_version_ 1782182472107163648
author Schwandt, Anita
Wood, Laura S
Rini, Brian
Dreicer, Robert
author_facet Schwandt, Anita
Wood, Laura S
Rini, Brian
Dreicer, Robert
author_sort Schwandt, Anita
collection PubMed
description Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and subsequently improvement in progression free survival in phase III renal cancer trials. We review the unique side effects of sunitinib therapy with emphasis on establishing effective patient education for anticipation and early management of therapy-related side effects.
format Text
id pubmed-2886329
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-28863292010-07-08 Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma Schwandt, Anita Wood, Laura S Rini, Brian Dreicer, Robert Onco Targets Ther Review Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and subsequently improvement in progression free survival in phase III renal cancer trials. We review the unique side effects of sunitinib therapy with emphasis on establishing effective patient education for anticipation and early management of therapy-related side effects. Dove Medical Press 2009-02-18 /pmc/articles/PMC2886329/ /pubmed/20616894 Text en © 2009 Schwandt et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Schwandt, Anita
Wood, Laura S
Rini, Brian
Dreicer, Robert
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
title Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
title_full Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
title_fullStr Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
title_full_unstemmed Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
title_short Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
title_sort management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886329/
https://www.ncbi.nlm.nih.gov/pubmed/20616894
work_keys_str_mv AT schwandtanita managementofsideeffectsassociatedwithsunitinibtherapyforpatientswithrenalcellcarcinoma
AT woodlauras managementofsideeffectsassociatedwithsunitinibtherapyforpatientswithrenalcellcarcinoma
AT rinibrian managementofsideeffectsassociatedwithsunitinibtherapyforpatientswithrenalcellcarcinoma
AT dreicerrobert managementofsideeffectsassociatedwithsunitinibtherapyforpatientswithrenalcellcarcinoma

Ejemplares similares